Why COMPASS Pathways (CMPS) Is Down 8.2% After New Phase 3 Data and Rolling NDA Update

• Compass Pathways recently reported 26-week results from its second Phase 3 COMP006 trial of COMP360 for treatment-resistant depression, showing rapid and durable symptom improvement alongside a generally well-tolerated safety profile in nearly 600 participants with highly chronic illness.
• The data suggest that a second 25 mg dose may enhance and extend clinical benefit for some patients, while the company advances a rolling New Drug Application with the FDA toward a potential US launch, subject to regulatory approval and DEA rescheduling.
• We’ll now examine how these 26-week Phase 3 results and the ongoing rolling NDA process could reshape COMPASS Pathways’ investment narrative.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

COMPASS Pathways Investment Narrative Recap

To own Compass Pathways, you have to believe COMP360 can clear late stage trials, gain FDA approval and be adopted in real world psychiatry settings. The new 26 week COMP006 data support efficacy and safety in a hard to treat population and appear to reinforce, rather than redefine, the key near term catalyst: completion of the rolling NDA and eventual FDA review. The biggest risk remains execution around approval, launch timing and cash needs ahead of meaningful revenue.

The most relevant recent announcement is Compass’s April update that the FDA granted a rolling NDA submission and National Priority Voucher consideration for COMP360 in treatment resistant depression. Together with the new 26 week COMP006 results, this creates a clearer regulatory path but also tightens the focus on regulatory outcomes, labeling details and any REMS requirements as critical swing factors for how powerful the first commercial launch can be.

Yet investors should also recognize that tighter labels or more restrictive REMS requirements could still limit how broadly COMP360 is used across treatment centers and...

Read the full narrative on COMPASS Pathways (it's free!)

COMPASS Pathways' narrative projects $193.1 million revenue and $24.2 million earnings by 2029. This requires revenue to grow from zero and a $261.5 million earnings increase from -$237.3 million today.

Uncover how COMPASS Pathways' forecasts yield a $21.92 fair value, a 69% upside to its current price.

Exploring Other Perspectives

Before this latest data, the most cautious analysts were only expecting about US$59.5 million of revenue and roughly US$6.5 million of earnings by 2029, so if you side with them you are effectively assuming that any regulatory hurdles or clinic workflow constraints will sharply cap COMP360’s long term potential even if today’s 26 week results eventually hold up.

Explore 4 other fair value estimates on COMPASS Pathways - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your COMPASS Pathways research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free COMPASS Pathways research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate COMPASS Pathways' overall financial health at a glance.

No Opportunity In COMPASS Pathways?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com